Article thumbnail

Increased Levels of Leukocyte-Derived MMP-9 in Patients with Stable Angina Pectoris

By Simon Jönsson, Anna Lundberg, Hanna Kälvegren, Ida Bergström, Aleksander Szymanowski and Lena Jonasson
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). Abnormal circulating neutrophil linked matrix metalloproteinase -9 in stable coronary artery disease.
  2. (2007). Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis
  3. (2010). Activation of peripheral blood mononuclear cells and extracellular matrix and inflammatory gene profile in acute myocardial infarction.
  4. (2008). Aggregatibacter actinomycetemcomitans induces MMP-9 expression and proatherogenic lipoprotein profile in apoE-deficient mice.
  5. (2003). Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis.
  6. (2006). Aspirin and salicylate suppress polymorphonuclear apoptosis delay mediated by proinflammatory stimuli.
  7. (2005). Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease.
  8. (2001). Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis.
  9. (1997). Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes.
  10. (2006). Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers.
  11. (2009). Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus.
  12. (2007). Divergent associations of tissue inhibitors of metalloproteinases-1 and -2 with the prothrombotic/fibrinolytic state. Atherosclerosis
  13. (2009). Effects of low-dose aspirin on acute inflammatory responses in humans.
  14. (2011). Elevated levels of circulating matrix metalloproteinase-9 are associated with a dysregulated cortisol rhythm—A case-control study of coronary artery disease. Psychoneuroendocrinology, In Press, Corrected Proof.
  15. (2006). Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis.
  16. (1997). Granules of the human neutrophilic polymorphonuclear leukocyte.
  17. (2010). High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis
  18. (1999). Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators.
  19. (2004). IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: The EPIC-norfolk prospective population study.
  20. (1968). Isolation of mononuclear cells and granulocytes from human blood. isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.
  21. (1976). Letter: Grading of angina pectoris.
  22. (2004). Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris.
  23. (2010). Matrix metalloproteinases in atherothrombosis.
  24. (2002). Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly.
  25. (2008). Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability.
  26. (2005). Metalloproteinases and their inhibitors are markers of plaque instability.
  27. (2008). Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.
  28. (2007). Neutrophil activation status in stable coronary artery disease.
  29. (2002). Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes.
  30. (1998). Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes.
  31. (2003). Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease.
  32. (2001). Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
  33. (2005). Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
  34. (2010). Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis
  35. (2007). Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.
  36. (2010). Relation of matrix metalloproteinase-9/ Tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
  37. (2002). Release and activation of matrix metalloproteinase 8 from human neutrophils triggered by the leukotoxin of actinobacillus actinomycetemcomitans.
  38. (1986). Secreted forms of human neutrophil collagenase.
  39. (2007). Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men.
  40. (2004). Simvastatin prevents vascular hyporeactivity during inflammation.
  41. (2000). Tissue inhibitors of metalloproteinases: Evolution, structure and function.
  42. (2004). Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity.